ALVOTECH

NASDAQ: ALVO (Alvotech)

Kemas kini terakhir: 03 Jan, 4:27PM

13.26

0.10 (0.76%)

Penutupan Terdahulu 13.16
Buka 13.25
Jumlah Dagangan 96,116
Purata Dagangan (3B) 117,325
Modal Pasaran 4,003,777,536
Harga / Jualan (P/S) 8.56
Julat 52 Minggu
9.15 (-30%) — 18.00 (35%)
Tarikh Pendapatan 13 Nov 2024
Margin Keuntungan -200.30%
Margin Operasi (TTM) 46.22%
EPS Cair (TTM) -1.85
Pertumbuhan Hasil Suku Tahunan (YOY) 4,399.70%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -65.50%
Nisbah Semasa (MRQ) 0.240
Aliran Tunai Operasi (OCF TTM) -310.18 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -287.74 M
Pulangan Atas Aset (ROA TTM) -7.61%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - Specialty & Generic (US) Bercampur Bercampur
Drug Manufacturers - Specialty & Generic (Global) Bercampur Bercampur
Stok Alvotech Bercampur Menaik

AISkor Stockmoo

2.5
Konsensus Penganalisis NA
Aktiviti Orang Dalam NA
Volatiliti Harga 1.0
Purata Bergerak Teknikal 2.5
Osilator Teknikal 4.0
Purata 2.50

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
ALVO 4 B - - -
ITCI 10 B - - 8.79
LNTH 6 B - 15.29 5.58
KNSA 1 B - - 3.35
HROW 1 B - - 22.53
CRON 768 M - - 0.710

Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.

Sektor Healthcare
Industri Drug Manufacturers - Specialty & Generic
Gaya Pelaburan Small Growth
% Dimiliki oleh Orang Dalam 64.01%
% Dimiliki oleh Institusi 6.04%

Pemilikan

Nama Tarikh Syer Dipegang
Lodbrok Capital Llp 30 Sep 2024 181,587
Oaktree Fund Advisors, Llc 30 Sep 2024 118,744

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
23 Dec 2024 Pengumuman Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024
23 Dec 2024 Pengumuman Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024
13 Nov 2024 Pengumuman Alvotech Reports Financial Results for the First Nine Months of 2024
13 Nov 2024 Pengumuman Alvotech Reports Financial Results for the First Nine Months of 2024
07 Nov 2024 Pengumuman Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024
07 Nov 2024 Pengumuman Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024
04 Nov 2024 Pengumuman European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
04 Nov 2024 Pengumuman European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
30 Oct 2024 Pengumuman Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET
30 Oct 2024 Pengumuman Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET
25 Oct 2024 Pengumuman Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024
25 Oct 2024 Pengumuman Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024
22 Oct 2024 Pengumuman Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
22 Oct 2024 Pengumuman Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda